167 related articles for article (PubMed ID: 24634505)
1. Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib.
Graham TJ; Box G; Tunariu N; Crespo M; Spinks TJ; Miranda S; Attard G; de Bono J; Eccles SA; Davies FE; Robinson SP
J Natl Cancer Inst; 2014 Apr; 106(4):dju033. PubMed ID: 24634505
[TBL] [Abstract][Full Text] [Related]
2. Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer.
Eswaraka J; Giddabasappa A; Han G; Lalwani K; Eisele K; Feng Z; Affolter T; Christensen J; Li G
BMC Cancer; 2014 Oct; 14():742. PubMed ID: 25277255
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling.
Nguyen HM; Ruppender N; Zhang X; Brown LG; Gross TS; Morrissey C; Gulati R; Vessella RL; Schimmoller F; Aftab DT; Corey E
PLoS One; 2013; 8(10):e78881. PubMed ID: 24205338
[TBL] [Abstract][Full Text] [Related]
4. Quantitative assessment of
Oya T; Ichikawa Y; Nakamura S; Tomita Y; Sasaki T; Inoue T; Sakuma H
Ann Nucl Med; 2023 Jun; 37(6):360-370. PubMed ID: 36947324
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries.
Doran MG; Spratt DE; Wongvipat J; Ulmert D; Carver BS; Sawyers CL; Evans MJ
Mol Imaging; 2014; 13():. PubMed ID: 25248353
[TBL] [Abstract][Full Text] [Related]
6. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.
Dai J; Zhang H; Karatsinides A; Keller JM; Kozloff KM; Aftab DT; Schimmoller F; Keller ET
Clin Cancer Res; 2014 Feb; 20(3):617-30. PubMed ID: 24097861
[TBL] [Abstract][Full Text] [Related]
8. Current role of cabozantinib in metastatic castration-resistant prostate cancer.
Fay AP; Albiges L; Bellmunt J
Expert Rev Anticancer Ther; 2015 Feb; 15(2):151-6. PubMed ID: 25586337
[TBL] [Abstract][Full Text] [Related]
9. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
Smith DC; Smith MR; Sweeney C; Elfiky AA; Logothetis C; Corn PG; Vogelzang NJ; Small EJ; Harzstark AL; Gordon MS; Vaishampayan UN; Haas NB; Spira AI; Lara PN; Lin CC; Srinivas S; Sella A; Schöffski P; Scheffold C; Weitzman AL; Hussain M
J Clin Oncol; 2013 Feb; 31(4):412-9. PubMed ID: 23169517
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer.
Vaishampayan UN; Podgorski I; Heilbrun LK; Lawhorn-Crews JM; Dobson KC; Boerner J; Stark K; Smith DW; Heath EI; Fontana JA; Shields AF
Clin Cancer Res; 2019 Jan; 25(2):652-662. PubMed ID: 30327304
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms.
Scott AJ; Arcaroli JJ; Bagby SM; Yahn R; Huber KM; Serkova NJ; Nguyen A; Kim J; Thorburn A; Vogel J; Quackenbush KS; Capasso A; Schreiber A; Blatchford P; Klauck PJ; Pitts TM; Eckhardt SG; Messersmith WA
Mol Cancer Ther; 2018 Oct; 17(10):2112-2122. PubMed ID: 30026382
[TBL] [Abstract][Full Text] [Related]
12. Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity.
Wang X; Huang Y; Christie A; Bowden M; Lee GS; Kantoff PW; Sweeney CJ
Clin Cancer Res; 2015 Dec; 21(24):5578-87. PubMed ID: 26289068
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
Smith MR; Sweeney CJ; Corn PG; Rathkopf DE; Smith DC; Hussain M; George DJ; Higano CS; Harzstark AL; Sartor AO; Vogelzang NJ; Gordon MS; de Bono JS; Haas NB; Logothetis CJ; Elfiky A; Scheffold C; Laird AD; Schimmoller F; Basch EM; Scher HI
J Clin Oncol; 2014 Oct; 32(30):3391-9. PubMed ID: 25225437
[TBL] [Abstract][Full Text] [Related]
14. The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer.
Al Nakouzi N; Bawa O; Le Pape A; Lerondel S; Gaudin C; Opolon P; Gonin P; Fizazi K; Chauchereau A
Neoplasia; 2012 May; 14(5):376-87. PubMed ID: 22745584
[TBL] [Abstract][Full Text] [Related]
15. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
Smith M; De Bono J; Sternberg C; Le Moulec S; Oudard S; De Giorgi U; Krainer M; Bergman A; Hoelzer W; De Wit R; Bögemann M; Saad F; Cruciani G; Thiery-Vuillemin A; Feyerabend S; Miller K; Houédé N; Hussain S; Lam E; Polikoff J; Stenzl A; Mainwaring P; Ramies D; Hessel C; Weitzman A; Fizazi K
J Clin Oncol; 2016 Sep; 34(25):3005-13. PubMed ID: 27400947
[TBL] [Abstract][Full Text] [Related]
16. Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis.
Lee C; Whang YM; Campbell P; Mulcrone PL; Elefteriou F; Cho SW; Park SI
Cancer Lett; 2018 Feb; 414():205-213. PubMed ID: 29174801
[TBL] [Abstract][Full Text] [Related]
17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
18. Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo.
Haider MT; Hunter KD; Robinson SP; Graham TJ; Corey E; Dear TN; Hughes R; Brown NJ; Holen I
Bone; 2015 Dec; 81():581-592. PubMed ID: 26279137
[TBL] [Abstract][Full Text] [Related]
19. Multimodal imaging provides insight into targeted therapy response in metastatic prostate cancer to the bone.
Hoff BA; Brisset JC; Galbán S; Van Dort M; Smith DC; Reichert ZR; Jacobson JA; Luker GD; Chenevert TL; Ross BD
Am J Nucl Med Mol Imaging; 2018; 8(3):189-199. PubMed ID: 30042870
[TBL] [Abstract][Full Text] [Related]
20. Head-to-head comparison of
Zhang Y; Lin Z; Li T; Wei Y; Yu M; Ye L; Cai Y; Yang S; Zhang Y; Shi Y; Chen W
Sci Rep; 2022 Sep; 12(1):15993. PubMed ID: 36163353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
